IGF-1 LR3

IGF-1 LR3 is a modified insulin-like growth factor analogue used in experimental research on growth signaling, glucose metabolism, protein synthesis, cell survival, and proliferation.

Activates the IGF-1 receptor and downstream PI3K–AKT–mTOR and RAS–MAPK pathways. Reduced binding to IGF-binding proteins may extend experimental activity relative to native IGF-1.

Predominantly preclinical for the LR3 analogue.

Level IV, Predominantly preclinical

Clinical evidence for approved recombinant IGF-1 products does not establish the safety or behavior of IGF-1 LR3.

Potential concerns include hypoglycemia, edema, tissue overgrowth, cardiac effects, and stimulation of proliferative signaling.

No FDA-approved IGF-1 LR3 drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.